A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease mainly on account of hypercholesterolemia and may progress to cirrhosis and hepatocellular carcinoma. The discovery of effective therapy for NAFLD is an essential unmet need. Angiopoietin-like protein 3 (ANGPTL3), a critical...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiaozhi, Fan, Jiajun, Ma, Qianqian, Han, Lei, Cao, Zhonglian, Xu, Caili, Luan, Jingyun, Jing, Guangjun, Nan, Yanyang, Wu, Tao, Zhang, Yuting, Wang, Hanqi, Zhang, Yuanzhen, Ju, Dianwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118633/
https://www.ncbi.nlm.nih.gov/pubmed/35590366
http://dx.doi.org/10.1186/s12951-022-01456-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118633/
https://www.ncbi.nlm.nih.gov/pubmed/35590366
http://dx.doi.org/10.1186/s12951-022-01456-z

Ejemplares similares